Biophoenix Limited

Biophoenix is a biomedical consultancy based in the heart of England, which was founded by Drs Sreten Bogdanovic and Beata Langlands. Originally established with support from the predecessor to the UK's Department for Business, Enterprise and Regulatory Reform (BERR) in 1994, Biophoenix provides detailed, accurate, market and technical information to support decision-making by biotechnology-based enterprises in the healthcare industry. In doing so, Biophoenix relies on its comprehensive in-house bioindustry database and a wide network of contacts. Biophoenix has researched and written over 50 in-depth management/market reports which have been published by clients such as Frost & Sullivan, the London Financial Times, Drug and Market Development Inc, Informa Healthcare (e.g.
Scrip and Clinica), and Business Insights (part of Datamonitor). Biophoenix has also audited biotechnology-based enterprises with regard to the risk of intellectual property litigation on behalf of several Lloyds of London insurers.

 

List of reports from Biophoenix Limited

Cancer Drugs With Apoptotic Targets In Development
7/1/2010 | published by: Biophoenix Limited
... one or more of over 40 genes involved in apoptosis (programmed cell death). Most current cancer therapies, including chemotherapeutic agents, work by inducing apoptosis in cancer cells. However, many cancer cells are resistant or develop ...  |  more...
$350.00
Biosimilars and Biobetters: Positioning for a New Market
7/1/2009 | published by: Biophoenix Limited
... of 12 biosimilar products have now been aproved. In the US a few follow-on-biologics (FOBs) of products regulated under NDAs have been approved, but there is no abbreviated approval pathway for biologics regulated under BLAs ...  |  more...
$1,000.00
Apoptosis 2009: Opportunities in Cancer and Other Diseases
2/6/2009 | published by: Biophoenix Limited
... we anticipate that this approach will pay substantial dividends, both therapeutically and commercially. This report reviews 370 apoptosis-modulating drug candidates, and reveals a transforming market offering growth potential in cancer and other indications. Apoptosis (programmed ...  |  more...
$1,000.00
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
7/15/2008 | published by: Biophoenix Limited
... individuals at risk of developing new or worsening cardiovascular disease (primary and secondary prevention). Antidyslipidemics on the market include statins, ezetimibe, fibrates, niacin products, bile acid sequestrants, and prescription omega-3 products. Many clinical trials over ...  |  more...
$3,000.00
 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!